Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation technique aims to shrink spine tumors with fewer side effects

NCT ID NCT06204315

Symptom relief Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to give radiation to people with cancer that has spread to the spine and is pressing on the spinal cord. The goal is to see if giving a slightly higher dose of radiation to the tumor while protecting the spinal cord is safe. About 60 adults with this condition will take part. If successful, this approach could help control the tumor and ease symptoms like pain or weakness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Greater than or equal to 18 years old 2. Radiographically documented spinal metastasis on spine MRI within 4 weeks of registration 3. Proximity of spinal metastasis to spinal cord or cauda equina which precludes achieving a GTV Dmin of at least 14 Gy per the PI 4. All participants must be able to receive single fraction SSRS at the site of interest with 0.01 cc of the spinal cord receiving 14-16 Gy and/or 0.01 cc of the cauda equina receiving 18-20 Gy. The goal of treatment is to select the minimal dose to the organ at risk which will achieve a GTV Dmin of 14 Gy at the treating physician's discretion. 5. Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session 6. All participants must be able to receive a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 Gy 7. All participants must have a vertebral level site of interest from C1 to S2 8. Signed informed consent 9. Diagnosis of cancer excluding ultra-radiosensitive histologies (see 4.2) 10. Motor strength ≥ 4 out of 5 in extremity or extremities affected by the level of cord compression 11. ECOG ≤ 2 Exclusion Criteria: 1. Participants with ultra-radiosensitive histologies (lymphoma, multiple myeloma/plasmacytoma) 2. Prior history of radiation at the spinal site of interest 3. Inability to lie supine comfortably for ≥ 60 minutes 4. Progressive neurological deficits due to compression 5. Inability of obtain an MRI 6. Inability or refusal to undergo an MR simulation 7. No eligible for single fraction SSRS for any reason 8. Participants who are pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic epidural are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epidural spinal canal neoplasm metastatic malignant neoplasm in the spinal cord spinal cord disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic epidural Spinal cord Spine stereotactic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.